Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.

Item

http://www.wikidata.org/entity/Q37358759

Q37358759

about

PEGylation of Interferon-β-1a AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice.A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.Effectiveness of daily versus non-daily granulocyte colony-stimulating factors in patients with solid tumours undergoing chemotherapy: a multivariate analysis of data from current practice.Clinical practice in febrile neutropenia risk assessment and granulocyte colony-stimulating factor primary prophylaxis of febrile neutropenia in Poland.Multicentre, Prospective Observational Study of Pegfilgrastim Primary Prophylaxis in Patients at High Risk of Febrile Neutropenia in Poland: PROFIL Study Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia.Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma.Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study.Chronic comorbid conditions associated with risk of febrile neutropenia in breast cancer patients treated with chemotherapy.Costs associated with febrile neutropenia in the US.Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33).Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database.A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice.Chemotherapy treatment patterns and neutropenia management in gastric cancer.An unusual cause of a marked leukocytosis and an abnormal blood film.Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.

P2860

Q22241420-15E85FAD-0B78-44D5-AB8E-20DD25A60D6F Q30318240-578DBEEB-094E-488D-987F-0E6A0BDC8E38 Q30975418-DCB789AE-5B6A-4B09-B45A-43E9FEB36FD2 Q33543823-380F6B7D-03B6-45D8-8AB6-16BE9725F8B6 Q33756369-13101BCE-0EAB-442C-BF20-91EA5A3F0074 Q33770736-D98CD02C-19B2-4823-97EB-2E18BBAB22AE Q34333814-ECDABD06-DCF3-4677-B173-33AA8E0D1780 Q34553998-4F452CE5-0490-48B1-9399-F6DD1C9E7009 Q35165571-DC5A5FDA-EB8D-4B48-86B9-15CDD8ADCD52 Q36243957-9B933AE7-8D8B-41C9-9148-49808BA5E736 Q36885665-5D646B84-C82F-4833-901C-78F3FDF6CAD1 Q37831314-C45352F1-FE0D-4F1F-9E9F-CB27CBA8A3F1 Q37996443-D0FF1D3F-CBD1-4E68-82C6-E38B66AF641C Q38072290-35B90124-CFEB-459B-80F6-2E3EFB91696E Q38195261-845BB8FA-C0D4-4A28-AA0F-7292EC8EACAB Q38405004-66B5A3C9-03F7-4D44-8A50-890DE91EE375 Q38613025-98DF1416-601C-4E19-B609-8CE0C661CA2E Q40242261-F68972EF-BDA3-4536-84CE-8035C717D887 Q40245653-42DB6BF6-5555-4E72-B220-311E44B7DC7C Q40255259-148DCE49-77D9-4093-BC70-1988293C238C Q40280346-D872A30A-4C3E-4891-9DF4-EF3B3014FC55 Q40294108-510575F0-4F08-4BE1-A21F-43920CB1AEC0 Q40346049-2AC0C8B0-388E-4BE4-A46F-115294B94C06 Q43571500-0BA9A4EE-652F-4873-9A64-2E5C00187091 Q45179487-CC564BA5-8F9F-417D-BBC2-B2E4EF7BD22B Q46057636-8790D05B-F360-477B-BFE3-B9AC1E449F07 Q47737414-E739EF60-DF13-46C2-9AE8-3F6E2394D6A7 Q53657728-881D3D8C-8519-4F6C-817B-3CD10B0A416E

P2860

Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.

Item

http://www.wikidata.org/entity/Q37358759

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 December 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs